SAN DIEGO–(BUSINESS WIRE)–SpineOvations, a San
Diego-based medical technology company focused on the development of new and
innovative products, announced today that it has been granted a patent in Europe for its novel injectable composition technology
for treatment and repair of any ligaments and tendons in the human body.

The patent, entitled “Implant for the Treatment of
Ligaments and Tendons,” has been issued by the European Patent Office. Although
similar injectable composition technology exists presently for use as dermal
fillers, this new invention satisfies the need for orthopedics and spine
procedures, such as treatment for Internal Disc Disruption (IDD), among other
ligament and tendon repair procedures throughout the body, while providing
ease-of-use benefits for the surgeon as well. The issued claims offer broad
protection of a technology platform developed by Neville Alleyne, M.D. and
Stuart Young, M.D.

“We are excited about our international patent
portfolio especially as it pertains to licensing our products globally, as well
as the increase in value of our intellectual property and therefore our
Company,” said SpineOvations CEO, M. Ross Simmonds. “This particular
whole body patent protection provides us and our licensees with a strong
marketing advantage over other products using similar active ingredients but it
in limited applications. Additionally, SpineOvations looks forward to
continuing to proactively build and strengthen its global intellectual property
portfolio moving forward – including applications for the patented technology
in the veterinary market.”

Simmonds added that a key application of SpineOvations
technology concept will also provide a method for alleviating pain symptoms in
a potentially enormous population of patients by delivering appropriate amounts
of collagen based material into ligaments and joints requiring repair.

SpineOvations is focused on the development of biocompatible
injectables for the stabilization of spinal disc integrity and for other
orthopedic applications, including non-surgical connective tissue repair. The
companys technology platform consists of a novel, non-surgical application for
identifying and treating spinal disc tears or fissures to seal and stabilize
the structural integrity of the spinal disc.

SpineOvations new treatment concept integrates the use of
discography with the administration of the companys DiscSeal™, an injectable
agent for soft tissue engineering, designed to fill and seal the disc defect
and provide internal disc stabilization and pain relief for the millions of
patients with chronic back pain as a result of internal disc derangement (IDD).
This innovative approach offers the potential to provide a cost-effective
treatment option for patients with chronic back pain that will delay or
possibly prevent the need for more invasive treatments such as surgery for
spinal fusion or disc replacement.

SpineOvations is a San Diego-based, privately held medical
device company focused on the development of novel, biocompatible injectables
for the stabilization of spinal disc integrity and for other orthopedic and
whole-body applications including non-surgical connective tissue repair. The
companys technology platform consists of a novel non-surgical application for
identifying and treating spinal discs that have tears or fissures in order to
seal the defect and improve structural integrity.

SpineOvations DiscSeal™ is a percutaneous injection
treatment for patients with Internal Disc Derangement (IDD) and suffering from
chronic, discogenic lower back pain. DiscSeal is designed to be an early-stage
treatment for those patients who have failed conservative care and who are not
yet candidates for the invasive surgical treatment options of total disc
replacement or spinal fusion, the largest segment of the spine market. For more
information, visit: http://www.spineovations.com/